Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
κ opioid receptor(Kappa opioid receptor) | 1 |
Target |
Mechanism κ opioid receptor agonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date23 Aug 2021 |
Target |
Mechanism CB2 modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CB1 agonists [+1] |
Active Org.- |
Originator Org. |
Active Indication- |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Start Date17 Feb 2023 |
Sponsor / Collaborator |
Start Date17 Jan 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Difelikefalin ( κ opioid receptor ) | Pruritus More | Approved |
CR-859 ( CB2 ) | Neuralgia More | Discontinued |
CR-701 ( CB1R x CB2 ) | Neuralgia More | Discontinued |
CZ-48 ( TOP1 ) | Lymphoma More | Pending |
CR-665 ( κ opioid receptor ) | Pain, Postoperative More | Pending |